News

Palisade Bio Secures $138 Million to Advance Clinical Programs

Palisade Bio Secures $138 Million to Advance Clinical Programs

Palisade Bio Secures Substantial Funding to Propel Clinical Trials

Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company dedicated to innovating therapies for autoimmune and inflammatory diseases, recently announced the successful closing of an impressive public offering, which raised gross proceeds of approximately $138 million. This significant amount will play a crucial role in advancing their upcoming Phase 2 clinical development program for PALI-2108, specifically targeting Ulcerative Colitis.

Description of the Offering and Key Participants

The offering was effectively managed by B Group Capital and Columbia Threadneedle Investments, boasting considerable support from notable investors such as Adage Capital Partners LP, Janus Henderson Investors, and RA Capital Management, among others. The collaborative effort of these experienced investors indicates a strong confidence in the potential breakthroughs that Palisade aims to achieve in the realm of inflammatory bowel diseases (IBD).

Highlighting the Leadership's Confidence

J.D. Finley, the CEO of Palisade Bio, expressed his enthusiasm regarding the overwhelming support from these reputable investors. "We are very pleased to have the backing of such high-quality, experienced investors who share our vision for the company," said Finley. He believes that this validation reflects not only the strength of the science behind their leading candidate, PALI-2108, but also the commitment to addressing urgent unmet medical needs in IBD.

Understanding PALI-2108

PALI-2108 is regarded as a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor poised to transform the treatment landscape for patients suffering from IBD. With these new funds, Palisade Bio is in a strong position to drive this promising therapeutic candidate through more robust clinical trials, providing hope for many patients living with chronic inflammatory diseases.

Details of the Public Offering

The public offering was made up of 197,154,844 shares at a public offering price of $0.70 each. It is essential to note that an additional inclusion was made with the full exercise of the underwriter’s over-allotment option, allowing for even greater fundraising potential to secure the future of Palisade's exciting clinical programs.

Role of Ladenburg Thalmann & Co. Inc.

Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for this significant offering, emphasizing the trust and professionalism that investors have in the company’s operations.

Future Plans and Strategic Focus

The funds raised will enable Palisade Bio not only to expedite the clinical studies of PALI-2108 but will also assist in developing a comprehensive strategy to maximize value for shareholders and address the pressing healthcare needs in the field of autoimmune diseases.

About Palisade Bio

As a clinical-stage company, Palisade Bio remains dedicated to advancing novel therapeutics that could dramatically improve the lives of patients living with autoimmune, inflammatory, and fibrotic conditions. Their commitment is to innovate treatment landscapes through a targeted approach, which aims to deliver meaningful solutions to unmet medical needs.

Investor and Media Contact

For further inquiries, interested parties can reach out to Jenene Thomas from JTC Team, LLC at 908-824-0775 or through email at PALI@jtcir.com for more information regarding Palisade Bio's operations and future plans.

Frequently Asked Questions

What is the significance of Palisade Bio's recent public offering?

The recent public offering raised $138 million, crucial for advancing their clinical programs, particularly the Phase 2 trial for PALI-2108 targeting Ulcerative Colitis.

Who participated in the public offering?

The offering included participation from reputable investors like Adage Capital Partners LP and Janus Henderson Investors, showcasing confidence in Palisade's vision.

What is PALI-2108 and its relevance?

PALI-2108 is a first-in-class PDE4 B/D inhibitor targeting IBD, aiming to address significant unmet medical needs in this field.

How does this funding impact shareholders?

This financing positions Palisade Bio to enhance its development strategy, benefiting shareholders by maximizing the company's value and clinical advancements.

Who to contact for more information about Palisade Bio?

Investor relations inquiries can be directed to Jenene Thomas at JTC Team, LLC, or via email at PALI@jtcir.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 13

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 67

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 136

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 78

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 63

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 58

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 59

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 80

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Technology Acquisition Corp. I Initiates Liquidation Process

Updated Category News Views 212

Global Technology Acquisition Corp. I Announces Dissolution of Operations Global Technology Acquisition Corp. I (Nasdaq: GTAC) finds itself at a pivotal moment, as the company has declared its intent to dissolve and liquidate its operations. This decision arises from the inability to complete an initial business combination within the mandated timeframe outlined in its...

Continue Reading
Empowering Leadership Development: McLean & Company Insights

Updated Category News Views 483

Leadership Development: Key to Organizational Success In today's fast-evolving work landscape, the significance of leadership development has never been clearer. Global HR research firm McLean & Company emphasizes that cultivating effective leaders at every level is crucial for organizational success. Their comprehensive research highlights a four-step process that...

Continue Reading
Investigation Launched into Aviat Networks, Inc. Securities Fraud

Updated Category News Views 144

Investigation into Aviat Networks, Inc. Recent developments regarding Aviat Networks, Inc. have raised significant concerns among investors about their financial future. The company is now under scrutiny from legal experts due to possible allegations of securities fraud. The Portnoy Law Firm is actively investigating these issues and has begun reaching out to investors...

Continue Reading
GR Silver Mining Plans $1.76 Million Private Placement Funding

Updated Category News Views 99

GR Silver Mining Ltd.'s Strategic Private Placement GR Silver Mining Ltd. (GRSL, GRSLF) has announced a plan to raise up to $1.76 million through a non-brokered private placement. This strategic initiative is designed to boost exploration efforts, particularly focusing on expanding resources at the San Marcial Area within the Plomosas Project. Details of the Offering The...

Continue Reading
BRT Apartments Corp. Declares Exciting New Dividend

Updated Category News Views 121

BRT Apartments Corp. announces a quarterly dividend BRT Apartments Corp. has declared a quarterly dividend of $0.25 per share. Approved by the Board of Directors, this action continues the company’s practice of returning cash to shareholders as part of its ongoing financial plan. It’s a straightforward move that underscores a focus on steady, shareholder-minded...

Continue Reading